129 related articles for article (PubMed ID: 10766284)
1. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
[TBL] [Abstract][Full Text] [Related]
2. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
[TBL] [Abstract][Full Text] [Related]
3. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
[TBL] [Abstract][Full Text] [Related]
4. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
5. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
7. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Williams GC; Orengo-Nania S; Gross RL
J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
[TBL] [Abstract][Full Text] [Related]
9. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions.
Butler P; Mannschreck M; Lin S; Hwang I; Alvarado J
Arch Ophthalmol; 1995 Mar; 113(3):293-6. PubMed ID: 7887842
[TBL] [Abstract][Full Text] [Related]
11. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
Nagasubramanian S; Hitchings RA; Demailly P; Chuniaud M; Pannarale MR; Pecori-Giraldi J; Stodtmeister R; Parsons DG
Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918
[TBL] [Abstract][Full Text] [Related]
12. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Nishimoto JH; Chang FW; Tang IH; Kolin T
J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
[TBL] [Abstract][Full Text] [Related]
13. High incidence of topical allergic reactions to 1% apraclonidine.
Feibel RM
Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638
[No Abstract] [Full Text] [Related]
14. Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
Gramer E; Busche S; Kampik A; Parsons D
Graefes Arch Clin Exp Ophthalmol; 1995 Jan; 233(1):13-20. PubMed ID: 7721118
[TBL] [Abstract][Full Text] [Related]
15. Exposure to topical apraclonidine in children with glaucoma.
Wright TM; Freedman SF
J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
[TBL] [Abstract][Full Text] [Related]
16. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A
Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713
[No Abstract] [Full Text] [Related]
17. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes.
Chung HS; Shin DH; Birt CM; Kim C; Lee D; Levin DS; Hakimzadeh R; Juzych MS
Ophthalmology; 1997 Nov; 104(11):1921-5. PubMed ID: 9373127
[TBL] [Abstract][Full Text] [Related]
18. Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
Hong C; Song KY
Korean J Ophthalmol; 1993 Jun; 7(1):28-33. PubMed ID: 7901442
[TBL] [Abstract][Full Text] [Related]
19. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
[TBL] [Abstract][Full Text] [Related]
20. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
